debate: hypomethylating agents are appropriate in lower-risk mds - only use with caution
Published 8 years ago • 184 plays • Length 20:13Download video MP4
Download video MP3
Similar videos
-
2:02
what are hypomethylating agents and when are they used for mds?
-
25:10
management of lower-risk mds without del5q and refractory to esas
-
13:55
debate: optimal approach for the management of cll patients with del(17p) - novel agents
-
1:12
hypomethylating agents for low risk mds
-
3:46
hypomethylating agents in the treatment of high-risk mds
-
4:48
hypomethylating agents in mds management
-
2:21
decitabine mechanism of action
-
2:55
american scientists david julius, ardem patapoutian win 2021 nobel prize for physiology or medicine
-
2:00
scientists are manipulating the dna of mosquitoes to fight the spread of malaria
-
14:03
debate: clinical scenarios in aml: traditional vs targeted therapy - traditional
-
6:57
hypomethylating agents in mds: factors to consider
-
25:20
promise and pitfalls in molecular testing in the diagnosis of mds
-
1:50
hypomethylating agent based combinations in mds
-
16:26
debate: is cr and mrd negativity still required in the era of novel agents? - no
-
22:41
new opportunities in experimental therapeutics in mds
-
22:13
how to approach hma failure?
-
24:18
atypical cml: diagnosis and management
-
15:31
debate: to maintain or not to maintain in myeloma? - no, but if you must, use a proteasome inhibitor
-
2:01
how should hypomethylating agents be used in combination therapy?
-
3:21
mode of action of hypomethylating agents for mds
-
15:59
debate: to maintain or not to maintain? immunomodulators vs. pi - no